Publications
75
Citations
9,891
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1994
This researcher's publication record spans a mix of topics including drug discovery for genetic metabolic diseases like Pompe disease, human genetics of neurodegenerative conditions (such as TDP-43 and UNC13A related ALS/frontotemporal dementia), and veterinary medicine studies on dogs (cardiology, oncology, and orthopedics). The work often combines genetics, translational drug development, and clinical evaluation, suggesting involvement in both human therapeutic research and veterinary clinical studies, though the connection between these areas is not clear from the publication record alone. Given the breadth of unrelated subfields, this may represent contributions from multiple distinct research collaborations or roles rather than a single cohesive research program.
Publication output has declined from a peak of 8 papers per year in 2017 to an average of about 3-4 papers per year over the last five years, though there was a slight uptick in 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction
Science Translational Medicine · 2026
- Laboratory safety evaluations of izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, for three-month alleviation of osteoarthritic pain in dogs
The Veterinary Journal · 2026
- Use of the <scp>IlluminOss</scp> Photodynamic Bone Stabilisation System Following Stereotactic Body Radiation Therapy for Limb‐Sparing in Six Dogs With Presumptive Appendicular Osteosarcoma
Veterinary and Comparative Oncology · 2026
- Pathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function
Nature Genetics · 2025
- Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders
Science Translational Medicine · 2024
- First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease
Clinical Pharmacology & Therapeutics · 2024
- FinnGen provides genetic insights from a well-phenotyped isolated population
Nature · 2023
- Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease
Journal of the American Society of Nephrology · 2023
- Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population
Nature · 2023
- Small molecule inhibition of glycogen synthase 1 restores autophagolysosomal and metabolic pathway dysfunction in a mouse model of Pompe disease
Molecular Genetics and Metabolism · 2023
- TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A
Nature · 2022
- Utility of cardiac MRI to diagnose myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease
American Journal of Veterinary Research · 2022
- Pharmacology of small molecule inhibitors of GYS1 in a mouse model of Pompe disease
Molecular Genetics and Metabolism · 2022
- Genetic reduction of muscle glycogen is well tolerated in UK Biobank participants
Molecular Genetics and Metabolism · 2022
- Substrate reduction therapy for Pompe disease: Small molecule inhibition of glycogen synthase 1 in preclinical models
Molecular Genetics and Metabolism · 2022
- Circulation×4
- Molecular Genetics and Metabolism×4
- Nature×3
- Proceedings of the National Academy of Sciences×3
- BMC Veterinary Research×3
- Jason Cowan
Medicine · The Ohio State University
- Heather R. Manring
Medicine · The Ohio State University
- Brandon J. Biesiadecki
Medicine · The Ohio State University
- Elizabeth A. Brundage
Medicine · The Ohio State University
- Ray E. Hershberger
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile